X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-jnjs-combination-therapy-patients-with-type-lung-cancer-2024-03-01/
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/
https://www.onclive.com/view/petrylak-provides-perspective-on-the-nationwide-cisplatin-carboplatin-shortage
https://endpts.com/cisplatin-carboplatin-shortages-raise-questions-about-impact-on-clinical-trials/
https://www.fiercepharma.com/pharma/fda-clears-more-chemotherapy-imports-chinas-qilu-amidst-shortage-key-cancer-meds
https://www.clinicaltrialsarena.com/news/debiopharm-first-patient-cancer-combo/
https://www.prnewswire.com/news-releases/lantern-pharma-selects-reprocell-usa-to-provide-support-for-the-phase-2-harmonic-clinical-trial-301812303.html
https://www.biospace.com/article/releases/qilu-pharmaceutical-releases-latest-results-of-ql1604-plus-chemotherapy-as-first-line-treatment-for-patients-with-advanced-cervical-cancer-in-the-phase-ii-study-at-esmo-asia-congress-2022/?s=95
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
https://www.prnewswire.com/news-releases/debiopharm-further-explores-the-potential-of-its-potent-highly-selective-wee1-inhibitor-debio-0123-in-phase-1-cancer-study-301446151.html
https://www.prnewswire.co.uk/news-releases/cantargia-expands-nadunolimab-development-in-non-squamous-nsclc-857354064.html
https://www.merck.com/news/merck-announces-phase-3-keynote-355-trial-met-primary-endpoint-of-overall-survival-os-in-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-cps-%E2%89%A510/
https://www.merck.com/news/merck-announces-phase-3-keynote-355-trial-met-primary-endpoint-of-overall-survival-os-in-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-cps-%E2%89%A510/
https://www.globenewswire.com/news-release/2021/07/12/2260981/19782/en/CytoDyn-s-Trial-for-Metastatic-Triple-Negative-Breast-Cancer-Demonstrates-Safety-with-350-mg-525-mg-and-700-mg-Dosages-Officially-Advances-to-Phase-2-from-Phase-1b.html
https://www.esmo.org/oncology-news/atezolizumab-with-carboplatin-as-immune-induction-shows-promise-in-metastatic-lobular-breast-cancer#:~:text=First%20results%20from%20a%20phase,patients%20with%20triple%20negative%20ILC.
http://www.pmlive.com/pharma_news/tecentriq_misses_the_mark_in_advanced_ovarian_cancer_1344780
http://www.pharmatimes.com/news/nice_final_guidance_backs_pfizers_lorviqua_1340196
https://www.fiercepharma.com/marketing/roche-s-tecentriq-chasing-merck-s-keytruda-nabs-another-nod-all-important-lung-cancer
https://www.biospace.com/article/releases/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-/?s=95
https://www.businesswire.com/news/home/20191016005264/en/Results-STELLAR-Trial-Tumor-Treating-Fields-Chemotherapy/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.biospace.com/article/releases/innovent-provides-update-on-the-results-of-ibi305-for-the-first-line-treatment-of-advanced-non-squamous-cell-lung-cancer-by-oral-presentation-at-csco/?s=95
https://endpts.com/roches-tecentriq-excels-in-another-lung-cancer-study/
http://www.pharmafile.com/news/528149/roche-celebrates-european-approval-tecentriq-combo-first-line-lung-cancer
https://www.fiercepharma.com/marketing/astrazeneca-s-imfinzi-hits-survival-goal-tees-up-small-cell-lung-cancer-i-o-fight-roche
https://www.biospace.com/article/astrazeneca-has-dazzled-in-recent-cancer-trials-but-faces-stiff-competition/
https://www.fiercepharma.com/pharma/roche-scores-first-global-nod-for-targeted-cancer-drug-rozlytrek
http://www.pharmatimes.com/news/new_lung_cancer_indication_for_keytruda_combo_okd_in_eu_1281600
https://www.prnewswire.com/news-releases/fda-expands-lillys-alimta-pemetrexed-label-with-combination-of-keytruda-pembrolizumab-and-platinum-chemotherapy-for-the-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer-300787242.html
https://www.pharmacompass.com/pdf/news/fda-accepts-roches-supplemental-biologics-license-application-for-tecentriq-plus-chemotherapy-1547719393.pdf
https://globenewswire.com/news-release/2018/12/07/1663551/0/en/FDA-approves-Roche-s-Tecentriq-in-combination-with-Avastin-and-chemotherapy-for-the-initial-treatment-of-people-with-a-specific-type-of-metastatic-lung-cancer.html
https://www.reuters.com/article/us-roche-hldg-fda/roches-lung-cancer-combo-treatment-wins-fda-approval-idUSKBN1O52KP
https://www.biospace.com/article/fd1a-fda-action-alert-merck-insed-and-antares-pharma/
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm?utm_campaign=Oncology%20Pembrolizumab%208%2F20%2F2018%20&utm_medium=email&utm_source=Eloqua&elqTrackId=863601bda2b24a2b8502899dc6cdb179&elq=2ea90427c3114c8c955797bf9c7a090e&elqaid=4707&elqat=1&elqCampaignId=3746
https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm?utm_campaign=FDA%20updates%20the%20prescribing%20information%20for%20Keytruda%20%28pembrolizumab%29%20and%20Tecentriq%20%28atezolizumab%29&utm_medium=email&utm_source=Eloqua
https://endpts.com/merck-claims-a-needed-win-for-keytruda-with-interim-os-data-in-head-and-neck-cancer/
http://www.pharmatimes.com/news/us_priority_review_for_keytrudachemo_combo_in_first-line_squamous_nsclc_1243027
http://www.pharmatimes.com/news/us_nod_for_alimtakeytruda_lung_cancer_combo_1238721
https://www.prnewswire.com/news-releases/fda-expands-lillys-alimta-pemetrexed-label-to-include-combination-with-keytruda-pembrolizumab-and-carboplatin-as-first-line-treatment-for-metastatic-nonsquamous-non-small-cell-lung-cancer-irrespective-of-pd-l1-expression-300659662.html
https://www.reuters.com/article/us-health-cancer-roche/roche-drugs-show-limited-benefit-in-lung-breast-cancer-trials-idUSKCN1IY0E4
Market Place
Share 
